EGFR and neoplasm: Another study showed that high expression of EGFR, with or without the presence of EGFR mutations, was a potentially useful tumor biomarker for predicting the survival benefit from first-line chemotherapy plus cetuximab in NSCLC.[35] Given the value of tumor biomarkers for predicting the survival benefit for patients with NSCLC, we will continue to develop different tumor biomarkers for clinical applications.